CClinicalTrials.gg
Active, not recruitingNCT04113603Updated Mar 20, 2026

Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography

An interventional study of Urinary malignancy in Urothelial Carcinoma, sponsored by Chang Gung Memorial Hospital. Active, not recruiting at 1 site in Taiwan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2019, registered Oct 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Single-bolus computed tomography urography (CTU)is a recently developed one-stop imaging examination for diagnosis of urinary tract diseases, including urinary malignancies. However, single-bolus CTU uses two post- contrast phases (i.e.: nephrographic and excretory phases) for diagnosis of urinary tract diseases. A further-developed split-bolus CTU uses solitary post-contrast phase containing mixed information of nephrographic and excretory phases for diagnosis of urinary tract disease; however, whether split-bolus CTU has similar high diagnostic values for urinary malignancies remains unaddressed. Thus, the aim of this study is to compare the diagnostic performance between single-bolus and split-bolus CTU for diagnosing urinary malignancies. This study will enroll 352 patients from two hospitals if they fit the including criteria including aged > 40 years old, presenting with gross hematuria or having urinary malignancies histories, normal renal function (i.e.: estimated glomerular filtration rate > 60 mL/min/1.73 m2, no allergic history to iodinated contrast medium and no pregnancy). All enrolled patients will be randomized to undergo split-bolus and single-bolus CTU in 1: 1 manner. Two radiologists will read CTU images independently using a standardized recording sheet with Likert scales 1-5 representing higher probabilities of presence of urinary malignancies for larger number). The diagnostic values of split-bolus and single-bolus CTU will analyzed using reference standards by final diagnoses of urinary malignancies (i.e.: presence of urinary malignancies based on histological examinations of cytology examinations, biopsies or surgical specimens). The diagnostic performance of split-bolus CTU and single- bolus CTU for urinary malignancies will be compared using areas under receiver operating curve (ROC) to determine whether there is presence of significant difference .

Read the detailed description

This study will enroll 352 patients. The calculation of sample size is according to the following equation:

n2=〖(Z∝+Zβ/2)〗\^2/〖(δ-\|ε\|)〗\^2 [p1(1-p1)/k+p1(1-p2)]

∝=0.05, β=0.2, δ=0.05, p1=0.96, p2=0.80 Then, the number of each arm patient should be ≥ 141 patients. However, if 20 % of the enrolled patients by fitting inclusion criteria are excluded by fitting exclusion criteria, the number of each arem should be ≥ 176 patients. Thus, this study plans to enroll 352 patients (for two arms). The enrolled patients are randomized to two groups (using single-bolus CTU versus using split-bolus CTU) using permuted block method.

02

Conditions studied

  • Urothelial Carcinoma
03

In context

Carcinoma, Transitional Cell

716 studies on the registry are indexed under Carcinoma, Transitional Cell; 201 are open to participants now.

This study's planned enrollment of 352 is above the median of 49 across 549 interventional studies indexed under Carcinoma, Transitional Cell.

Browse Carcinoma, Transitional Cell studies →

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,064 studies on the registry; 235 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Fitting all of the followings

  1. age ≥ 40 years old
  2. presenting with gross hematuria or having a history of urothelial carcinomas
  3. normal renal function (i.e.: estimated glomerular filtration rate ≧ 60 mL/min/1.73 m2)
  4. no allergy history of iodinated contrast medium

Exclusion Criteria: Fitting any of the followings

  1. pregnant or lactating woman
  2. withdrawal of informed consent
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
352 participants (estimated)

Study arms

  • Experimental
    A_Single bolus

    Single bolus computed tomography urography (CTU)

    Diagnostic Test: Urinary malignancy

  • Experimental
    B_Split bolus

    Split bolus computed tomography urography (CTU)

    Diagnostic Test: Urinary malignancy

Interventions

  • Diagnostic testUrinary malignancy

    Single bolus three phase CTU

06

What researchers measure

Primary outcomes

  1. diagnostic values of urothelial carcinoma

    sensitivity, specificity, accuracy, area under ROC

    Time frame: 3 years

Secondary outcomes

  1. radiation dose

    radiation dose of single bolus versus split bolus CTU

    Time frame: 3 years

Other outcomes

  1. diagnostic values of other urinary tract diseases

    sensitivity, specificity and accuracy

    Time frame: 3 years

07

Study locations

1 site
  • Li-Jen Wang
    Taoyuan, Ta 333, Taiwan
08

References and documents

Individual participant data

Plan to share: No — Plan to make individual participant data

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04113603
Lead sponsor
Chang Gung Memorial Hospital
Responsible party
Li-Jen Wang (Medical Imaging Department Director, Chang Gung Memorial Hospital) — Principal investigator
First posted
Oct 3, 2019
Start date
Jun 1, 2019
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 20, 2026

Study contacts

Li-Jen Wang, M.D., M.P.H.
principal investigator · Chang Gung Memorial Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion